Taubenberger had led NIAID in an acting capacity since April 2025, but the timing and reason for his departure remain unclear; researchers had circulated reports roughly 2 weeks ago that he had stepped down.
HHS has not answered repeated questions about his status, and NIAID’s website still listed him as acting director on Thursday even as the employee directory identified him as chief of the viral pathogenesis and evolution section.
The departure leaves another apparent leadership vacancy at the NIH, adding uncertainty at the agency’s main infectious-disease institute.
Why are top infectious disease experts leaving the NIH during a time of growing global health threats?
With NIAID refocusing away from pandemics, who will now lead America's defense against emerging viruses?
Amidst leadership changes and budget cuts, what does the future hold for America's medical research grants?